Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Melanoma treatment has advanced significantly with novel therapeutic strategies.
• Oncolytic viruses (OVs) offer a new approach, selectively destroying tumor cells and stimulating antitumor immunity.
• Talimogene laherparepvec (T-VEC), a modified herpes simplex virus (HSV), is the first FDA-approved OV for melanoma.

Purpose of the Study:

• To review the role of OVs and T-VEC in melanoma monotherapy and combination treatments.
• To explore the application of T-VEC in other cutaneous cancers.
• To share clinical experiences with T-VEC therapy to guide future applications.

Main Methods:

• Literature review of oncolytic virus therapy in melanoma.
• Analysis of T-VEC efficacy in monotherapy and combination with immune checkpoint inhibitors (ICIs).
• Review of ongoing clinical trials evaluating T-VEC for various cancers.

Main Results:

• T-VEC demonstrates promising therapeutic effects in advanced melanoma.
• Combination therapy with T-VEC and ICIs shows enhanced antitumor responses.
• T-VEC is being investigated for efficacy across a spectrum of other cancer types.

Conclusions:

• Oncolytic virus therapy, particularly T-VEC, represents a significant advancement in melanoma treatment.
• T-VEC holds potential for treating various cutaneous cancers beyond melanoma.
• Further research and clinical experience are crucial for optimizing T-VEC's therapeutic utility.